首站-论文投稿智能助手
典型文献
Tumor-targeting intravenous lipid emulsion of paclitaxel:Characteristics,stability,toxicity,and toxicokinetics
文献摘要:
Lipid nanoemulsions are promising nanodrug delivery carriers that can improve the efficacy and safety of paclitaxel(PTX).However,no intravenous lipid emulsion of PTX has been approved for clinical treatment,and systemic safety profiles have not yet been reported.Here we outline the development of a PTX-loaded tumor-targeting intravenous lipid emulsion(PTX Emul)and describe its characteristics,colloidal stability,and systemic safety profiles in terms of acute toxicity,long-term toxicity,and tox-icokinetics.We also compare PTX Emul with conventional PTX injection.Results showed that PTX Emul exhibited an ideal average particle size(approximately 160 nm)with narrow size distribution and robust colloidal stability under different conditions.Hypersensitivity reaction and hemolysis tests revealed that PTX Emul did not induce hypersensitivity reactions and had no hemolytic potential.In addition,where the alleviated systemic toxicity of PTX Emul may be attributed to the altered toxicokinetic characteristics in beagle dogs,including the decreased AUC and increased plasma clearance and volume of distribution,PTX Emul alleviated acute and long-term toxicity as evidenced by the enhanced the median lethal dose and approximate lethal dose,moderate body weight change,decreased bone marrow suppression and organ toxicity compared with those under PTX injection at the same dose.A fundamental understanding of the systemic safety profiles,high tumor-targeting efficiency,and superior antitumor activity in vivo of PTX Emul can provide powerful evidence of its therapeutic potential as a future treatment for breast cancer.
文献关键词:
作者姓名:
Jun Ye;Lin Li;Jiye Yin;Hongliang Wang;Renjie Li;Yanfang Yang;Yongbiao Guan;Xuejun Xia;Yuling Liu
作者机构:
State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,100050,China;Beijing Key Laboratory of Drug Delivery Technology and Novel Formulation,Institute of Materia Medica,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,100050,China;National Beijing Center for Drug Safety Evaluation and Research,Beijing Institute of Pharmacology and Toxicology,Academy of Military Medical Sciences,Beijing,100850,China
引用格式:
[1]Jun Ye;Lin Li;Jiye Yin;Hongliang Wang;Renjie Li;Yanfang Yang;Yongbiao Guan;Xuejun Xia;Yuling Liu-.Tumor-targeting intravenous lipid emulsion of paclitaxel:Characteristics,stability,toxicity,and toxicokinetics)[J].药物分析学报(英文),2022(06):901-912
A类:
Emul,icokinetics,Hypersensitivity,toxicokinetic,beagle
B类:
Tumor,targeting,intravenous,lipid,paclitaxel,Characteristics,stability,toxicity,toxicokinetics,Lipid,nanoemulsions,promising,nanodrug,delivery,carriers,that,improve,efficacy,safety,PTX,However,has,been,approved,clinical,treatment,systemic,profiles,have,not,yet,reported,Here,outline,development,loaded,describe,its,characteristics,colloidal,terms,acute,long,We,also,conventional,injection,Results,showed,exhibited,ideal,average,particle,size,approximately,narrow,distribution,robust,different,conditions,hemolysis,tests,revealed,did,induce,hypersensitivity,reactions,had,hemolytic,potential,In,addition,where,alleviated,may,attributed,altered,dogs,including,decreased,increased,plasma,clearance,volume,evidenced,by,enhanced,median,lethal,dose,moderate,body,weight,change,bone,marrow,suppression,organ,compared,those,same,fundamental,understanding,high,efficiency,superior,antitumor,activity,vivo,provide,powerful,therapeutic,future,breast,cancer
AB值:
0.492323
相似文献
Targeting the Rac1 pathway for improved prostate cancer therapy using polymeric nanoparticles to deliver of NSC23766
Zean Li;Jun Huang;Tao Du;Yiming Lai;Kaiwen Li;Man-Li Luo;Dingjun Zhu;Jun Wu;Hai Huang-Department of Urology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510220,China;Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Medical Research Center,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;School of Biomedical Engineering,Sun Yat-sen University,Shenzhen 518107,China;Department of Obstetrics and Gynecology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Department of Urology,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China
Preclinical studies of the triazol0[1,5-a]pyrimidine derivative WS-716 as a highly potent,specific and orally active P-glycoprotein(P-gp)inhibitor
Sai-Qi Wang;Qiu-Xu Teng;Shuai Wang;Zi-Ning Lei;Hui-Hui Hu;Hui-Fang Lv;Bei-Bei Chen;Jian-Zheng Wang;Xiao-Jing Shi;Wei-Feng Xu;Hong-Min Liu;Xiao-Bing Chen;Zhe-Sheng Chen;Bin Yu-Department of Oncology,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Henan Cancer Institute,Zhengzhou 450008,China;State Key Laboratory of Esophageal Cancer Prevention&Treatment,Zhengzhou University,Zhengzhou 450052,China;College of Pharmacy and Health Sciences,St.John,s University,Queens,NY 11439,USA;School of Pharmaceutical Sciences,Zhengzhou University,Zhengzhou 450001,China;Laboratory Animal Center,Academy of Medical Science,Zhengzhou University,Zhengzhou 450052,China
Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity
Chuan-jing Cheng;Kai-xin Liu;Man Zhang;Fu-kui Shen;Li-li Ye;Wen-bo Wu;Xiao-tao Hou;Er-wei Hao;Yuan-yuan Hou;Gang Bai-State Key Laboratory of Medicinal Chemical Biology,College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research,Nankai University,Tianjin 300353,China;Collaborative Innovation Center of Research on Functional Ingredients from Agricultural Residues,Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica,Guangxi University of Chinese medicine,Nanning 530200,China;China-ASEAN Joint Laboratory for International Cooperation in Traditional Medicine Research,Guangxi University of Chinese Medicine,Nanning 530200,China
Pharmacodynamic,pharmacokinetic,and phase 1a study of bisthianostat,a novel histone deacetylase inhibitor,for the treatment of relapsed or refractory multiple myeloma
Yu-bo Zhou;Yang-ming Zhang;Hong-hui Huang;Li-jing Shen;Xiao-feng Han;Xiao-bei Hu;Song-da Yu;An-hui Gao;Li Sheng;Ming-bo Su;Xiao-li Wei;Yue Zhang;Yi-fan Zhang;Zhi-wei Gao;Xiao-yan Chen;Fa-jun Nan;Jia Li;Jian Hou-National Center for New Drug Screening,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Yantai Key Laboratory of Nanomedicine&Advanced Preparations,Yantai Institute of Materia Medica,Yantai 264000,China;Department of Hematology,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Shanghai Center for Drug Metabolism and Pharmacokinetics Research,Shanghai 201203,China
Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis
Ying Dong;Bi-xi Tang;Qi Wang;Li-wei Zhou;Cong Li;Xuan Zhang;Dan-dan Sun;Xin Sun;Xue-mei Zhang;Bing Xiong;Jia Li;Hong Shi;Dan-qi Chen;Yi Zang-State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Department of Pharmacology,School of Pharmacy,Fudan University,Shanghai 201203,China;Department of Medicinal Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Center for Supramolecular Chemistry and Catalysis and Department of Chemistry,College of Sciences,Shanghai University,Shanghai 200444,China;Schoolof Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing 210023,China;Schoolof Pharmacy,Henan University,Kaifeng 475004,China;Open Studio for Druggability Research of Marine Natural Products,Pilot National Laboratory for Marine Science and Technology(Qingdao),Qingdao 266237,China;School of Pharmaceutical Science and Technology,Hangzhou Institute for Advanced Study,UCAS,Hangzhou 310024,China;Department of Anesthesiology of Shanghai Pulmonary Hospital,School of medicine,Tongji University,Shanghai 200433,China
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。